These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 30671662)

  • 1. HIF Inhibitors: Status of Current Clinical Development.
    Fallah J; Rini BI
    Curr Oncol Rep; 2019 Jan; 21(1):6. PubMed ID: 30671662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer.
    Chung C
    Am J Health Syst Pharm; 2020 Dec; 77(24):2064-2073. PubMed ID: 33016992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
    Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
    Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
    Kim WY; Kaelin WG
    Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Carroll VA; Ashcroft M
    Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma.
    Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Vasko J; Ljungberg B
    Clin Cancer Res; 2005 Feb; 11(3):1129-35. PubMed ID: 15709180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
    Joshi S; Singh AR; Durden DL
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development.
    Rasmussen N; Rathmell WK
    Curr Clin Pharmacol; 2011 Aug; 6(3):199-206. PubMed ID: 21470103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
    Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
    Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof].
    Zhang N; Gong K; Yang XY; Xin DQ; Na YQ
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(22):1526-9. PubMed ID: 16854277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule.
    Welsh SJ; Dale AG; Lombardo CM; Valentine H; de la Fuente M; Schatzlein A; Neidle S
    Sci Rep; 2013 Sep; 3():2799. PubMed ID: 24165797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
    Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
    Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
    Rustum YM; Chintala S; Durrani FA; Bhattacharya A
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
    Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
    Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.